COSTA MESA, Calif., March 31 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) today announced the implementation of its agreement to roll out referenced-EEG(R) (rEEG(R)) availability with an undisclosed, national managed behavioral health organization (MBHO). This agreement enables psychiatrists under the management of the MBHO to utilize CNS Response's rEEG medication guidance to treat their most therapy-challenged patients suffering any of the behavioral disorders with the exception of schizophrenia. MBHO's contract with managed care companies and employers to manage the behavioral health benefits of their health plans toward appropriateness, efficacy, and efficiency.
George Carpenter, CNSO President specified, "Although we worked out the parameters of the contract earlier last year, this month we completed agreement on all key elements of our first rEEG implementation with a major MBHO. Those elements included patient qualifications, CNSO laboratory certification, rEEG reimbursement codes and rates, behavioral network training and network support services.
"Importantly, this is not a 'pilot program.' Our client concluded that, given the level of unmet clinical need among treatment-resistant populations, implementation was in the best interest of its corporate clients and their employees."
Daniel Hoffman, MD, Chief Medical Officer for CNS Response, explained, "It is not just that rEEG has been successful in guiding doctors in the majority of hard-to-treat cases. It is also the fact that, until now, physicians have had little evidence to support other approaches. This was demonstrated by a very large National Institute of Mental Health study, STAR*D, published last year. I think the combination of these two points is responsible for the attention CNS Response is now receiving."
Len Brandt, Chairman and CEO of CNS Response, commented, "We are enthused to begin implementing our first payer contract. We expect it will be the first of many as we commence commercialization to the managed care sector, though our goals are relatively modest for 2008. As this is our first program, we have elected to introduce the service to the MBHO in a controlled manner to be sure that our system of support to the physician and the payer are able to deliver high quality training and service. We will begin the implementation for some of its largest clients in the East before introducing this program to others.
"rEEG provides medication guidance custom to the individual patient based on the functioning of that patient's individual brain. We need to be very clear, while this information has shown to be relevant and particularly valuable for hard-to-treat patients, it is not at all the only information a physician will use to devise medication strategies. Patient presentation of symptoms; disease and treatment history; family history; other, pre-existing medical conditions; and the unique aspects attributable to each of these psychoactive medications when used individually or in combinations are necessary consideration by the physician.
"I would be disappointed if anyone presumed rEEG was a simple answer that would allow avoidance of these complex issues. I think it is important that patients, their families, their physicians and their payers accurately understand the contribution of rEEG. It is a valuable tool that adds important information to determination of a treatment, but that determination of treatment is still necessarily considerate of these complex issues. Having said that, all studies ever conducted have shown that trained physicians using rEEG have been vastly more successful in the treatment of hard-to-treat patients than has ever been consistently reported in refereed scientific literature or refereed scientific posters. Consequently, we feel rEEG is very valuable information for well-trained physicians when used in concert with other medical data and necessary considerations."
About CNS Response
CNS Response is a life-sciences data company focused on the commercialization of the first patented commercial system that guides psychiatrists and other physicians to determine proper treatments for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(R) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.
rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS Response is also an aide to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters
discussed are forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995, as
amended. These statements involve risks and uncertainties as set forth in
the Company's filings with the Securities and Exchange Commission. These
risks and uncertainties could cause actual results to differ materially
from any forward-looking statements made herein.
Jason Rando / Jennifer Saunders
(646) 536-7033 / 7011
|SOURCE CNS Response, Inc.|
Copyright©2008 PR Newswire.
All rights reserved